Medpace Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for Medpace Holdings (MEDP).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

4Buy

10Hold

Consensus RatingHold# Analysts14Avg. Consensus PT$534Upside to Avg. PT-16.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$665→$700
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Equal-Weight	$600→$625
Sep 30, 2026	UBS	Kevin Caliendo	Upgrade	Sell→Neutral	$405→$673
Jul 24, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$586→$665
Jul 24, 2026	BMO Capital	Sean Dodge	PT Raise	Market Perform	$400→$600
Jul 24, 2026	Truist Securities	Jailendra Singh	PT Raise	Hold	$462→$609
Jul 24, 2026	TD Cowen	Charles Rhyee	PT Raise	Hold	$419→$492
Jul 24, 2026	RBC Capital	Ryan Halsted	PT Raise	Outperform	$484→$692
Jul 24, 2026	Baird	Eric Coldwell	PT Raise	Neutral	$547→$624
Jul 13, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$495→$586
Jul 8, 2026	Baird	Eric Coldwell	Downgrade	Outperform→Neutral	$477→$547
Jul 7, 2026	Jefferies	David Windley	Downgrade	Buy→Hold	$490→$515
Apr 24, 2026	Barclays	Luke Sergott	PT Cut	Equal-Weight	$500→$450
Apr 24, 2026	BMO Capital	Sean Dodge	PT Cut	Market Perform	$460→$400
Apr 24, 2026	RBC Capital	Ryan Halsted	PT Cut	Outperform	$522→$484
Apr 24, 2026	Baird	Eric Coldwell	PT Cut	Outperform	$565→$477
Mar 6, 2026	Barclays	Luke Sergott	Upgrade	Underweight→Equal-Weight	$500
Mar 3, 2026	RBC Capital	Ryan Halsted	Initiate	Outperform	$522
Feb 18, 2026	TD Cowen	Charles Rhyee	Upgrade	Sell→Hold	$462→$419
Feb 13, 2026	Jefferies	David Windley	Upgrade	Hold→Buy	$560

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700

Mizuho analyst Ann Hynes maintains Medpace Holdings (NASDAQ:MEDP) with a Outperform and raises the price target from $665 to $700.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Medpace Holdings, Raises Price Target to $625

Barclays analyst Luke Sergott maintains Medpace Holdings (NASDAQ:MEDP) with a Equal-Weight and raises the price target from $600 to $625.

Benzinga Newsdesk

PRO
UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

UBS analyst Kevin Caliendo upgrades Medpace Holdings (NASDAQ:MEDP) from Sell to Neutral and raises the price target from $405 to $673.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665

Mizuho analyst Ann Hynes maintains Medpace Holdings (NASDAQ:MEDP) with a Outperform and raises the price target from $586 to $665.

Benzinga Newsdesk

PRO
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600

BMO Capital analyst Sean Dodge maintains Medpace Holdings (NASDAQ:MEDP) with a Market Perform and raises the price target from $400 to $600.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $609

Truist Securities analyst Jailendra Singh maintains Medpace Holdings (NASDAQ:MEDP) with a Hold and raises the price target from $462 to $609.

Benzinga Newsdesk

Medpace Holdings Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Medpace Holdings Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700

PRO
Barclays Maintains Equal-Weight on Medpace Holdings, Raises Price Target to $625

PRO
UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665

PRO
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600

PRO
Truist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $609

People Also Watch

People Also Watch

Medpace Holdings Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Medpace Holdings Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700

PROBarclays Maintains Equal-Weight on Medpace Holdings, Raises Price Target to $625

PROUBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

PROMizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665

PROBMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600

PROTruist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $609

People Also Watch

People Also Watch

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700

PRO
Barclays Maintains Equal-Weight on Medpace Holdings, Raises Price Target to $625

PRO
UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665

PRO
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600

PRO
Truist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $609